Unknown

Dataset Information

0

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.


ABSTRACT: PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ?2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%.

SUBMITTER: Fernandez-Martinez A 

PROVIDER: S-EPMC5400635 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.

Fernandez-Martinez Aranzazu A   Pascual Tomás T   Perrone Giuseppe G   Morales Serafin S   de la Haba Juan J   González-Rivera Milagros M   Galván Patricia P   Zalfa Francesca F   Amato Michela M   Gonzalez Lucia L   Prats Miquel M   Rojo Federico F   Manso Luis L   Paré Laia L   Alonso Immaculada I   Albanell Joan J   Vivancos Ana A   González Antonio A   Matito Judit J   González Sonia S   Fernandez Pedro P   Adamo Barbara B   Muñoz Montserrat M   Viladot Margarita M   Font Carme C   Aya Francisco F   Vidal Maria M   Caballero Rosalía R   Carrasco Eva E   Altomare Vittorio V   Tonini Giuseppe G   Prat Aleix A   Martin Miguel M  

Oncotarget 20170301 13


PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evalu  ...[more]

Similar Datasets

2011-06-20 | E-GEOD-26338 | biostudies-arrayexpress
| S-ECPF-GEOD-26338 | biostudies-other
| S-EPMC5449267 | biostudies-literature
| S-EPMC6656445 | biostudies-literature
| S-EPMC6498671 | biostudies-literature
| S-EPMC8172481 | biostudies-literature
| S-EPMC2970720 | biostudies-literature
| S-EPMC8037951 | biostudies-literature
| S-EPMC3336833 | biostudies-other
| S-EPMC4554253 | biostudies-literature